BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 31585940)

  • 1. S100A10 Is a Critical Mediator of GAS6/AXL-Induced Angiogenesis in Renal Cell Carcinoma.
    Xiao Y; Zhao H; Tian L; Nolley R; Diep AN; Ernst A; Fuh KC; Miao YR; von Eyben R; Leppert JT; Brooks JD; Peehl DM; Giaccia AJ; Rankin EB
    Cancer Res; 2019 Nov; 79(22):5758-5768. PubMed ID: 31585940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gas6-Axl signaling in presence of Sunitinib is enhanced, diversified and sustained in renal tumor cells, resulting in tumor-progressive advantages.
    Gustafsson A; Fritz HKM; Dahlbäck B
    Exp Cell Res; 2017 Jun; 355(1):47-56. PubMed ID: 28327411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.
    Rankin EB; Fuh KC; Castellini L; Viswanathan K; Finger EC; Diep AN; LaGory EL; Kariolis MS; Chan A; Lindgren D; Axelson H; Miao YR; Krieg AJ; Giaccia AJ
    Proc Natl Acad Sci U S A; 2014 Sep; 111(37):13373-8. PubMed ID: 25187556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gas6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma.
    Gustafsson A; Boström AK; Ljungberg B; Axelson H; Dahlbäck B
    PLoS One; 2009 Oct; 4(10):e7575. PubMed ID: 19888345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival.
    Gustafsson A; Martuszewska D; Johansson M; Ekman C; Hafizi S; Ljungberg B; Dahlbäck B
    Clin Cancer Res; 2009 Jul; 15(14):4742-9. PubMed ID: 19567592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
    Zhou L; Liu XD; Sun M; Zhang X; German P; Bai S; Ding Z; Tannir N; Wood CG; Matin SF; Karam JA; Tamboli P; Sircar K; Rao P; Rankin EB; Laird DA; Hoang AG; Walker CL; Giaccia AJ; Jonasch E
    Oncogene; 2016 May; 35(21):2687-97. PubMed ID: 26364599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model.
    Chen TJ; Mydel P; Benedyk-Machaczka M; Kamińska M; Kalucka U; Blø M; Furriol J; Gausdal G; Lorens J; Osman T; Marti HP
    Physiol Rep; 2021 Dec; 9(23):e15140. PubMed ID: 34877810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Landscape of prognostic signatures and immunogenomics of the AXL/GAS6 axis in renal cell carcinoma.
    Hakozaki K; Tanaka N; Takamatsu K; Takahashi R; Yasumizu Y; Mikami S; Shinojima T; Kakimi K; Kamatani T; Miya F; Tsunoda T; Aimono E; Nishihara H; Mizuno R; Oya M
    Br J Cancer; 2021 Nov; 125(11):1533-1543. PubMed ID: 34611307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rac Signaling Drives Clear Cell Renal Carcinoma Tumor Growth by Priming the Tumor Microenvironment for an Angiogenic Switch.
    Goka ET; Chaturvedi P; Lopez DTM; Lippman ME
    Mol Cancer Ther; 2020 Jul; 19(7):1462-1473. PubMed ID: 32371578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
    Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
    Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies.
    Kariolis MS; Miao YR; Diep A; Nash SE; Olcina MM; Jiang D; Jones DS; Kapur S; Mathews II; Koong AC; Rankin EB; Cochran JR; Giaccia AJ
    J Clin Invest; 2017 Jan; 127(1):183-198. PubMed ID: 27893463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA HOTAIR regulates HIF-1α/AXL signaling through inhibition of miR-217 in renal cell carcinoma.
    Hong Q; Li O; Zheng W; Xiao WZ; Zhang L; Wu D; Cai GY; He JC; Chen XM
    Cell Death Dis; 2017 May; 8(5):e2772. PubMed ID: 28492542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma.
    Yu H; Liu R; Ma B; Li X; Yen HY; Zhou Y; Krasnoperov V; Xia Z; Zhang X; Bove AM; Buscarini M; Parekh D; Gill IS; Liao Q; Tretiakova M; Quinn D; Zhao J; Gill PS
    Br J Cancer; 2015 Aug; 113(4):616-25. PubMed ID: 26180925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer.
    Tanaka M; Siemann DW
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteolin inhibits angiogenesis by blocking Gas6/Axl signaling pathway.
    Li X; Chen M; Lei X; Huang M; Ye W; Zhang R; Zhang D
    Int J Oncol; 2017 Aug; 51(2):677-685. PubMed ID: 28627676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gas6-induced tissue factor expression in endothelial cells is mediated through caveolin-1-enriched microdomains.
    Laurance S; Aghourian MN; Jiva Lila Z; Lemarié CA; Blostein MD
    J Thromb Haemost; 2014; 12(3):395-408. PubMed ID: 24354620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis.
    Kariolis MS; Miao YR; Jones DS; Kapur S; Mathews II; Giaccia AJ; Cochran JR
    Nat Chem Biol; 2014 Nov; 10(11):977-83. PubMed ID: 25242553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
    Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
    Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic aspects of the Axl/Gas6 molecular system.
    Di Stasi R; De Rosa L; D'Andrea LD
    Drug Discov Today; 2020 Dec; 25(12):2130-2148. PubMed ID: 33002607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib activates Axl signaling in renal cell cancer.
    van der Mijn JC; Broxterman HJ; Knol JC; Piersma SR; De Haas RR; Dekker H; Pham TV; Van Beusechem VW; Halmos B; Mier JW; Jiménez CR; Verheul HM
    Int J Cancer; 2016 Jun; 138(12):3002-10. PubMed ID: 26815723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.